These data indicate that CXCL10 is objectively measurable and its concentration can increase in the blood of patients with HCC—supporting its future examination as a potential biomarker of the immunomodulatory activity of regorafenib treatment. The gene discussed is CXCL10; the disease is hepatocellular carcinoma.